Rapid Micro Biosystems, Inc. RPID

Company Overview

Rapid Micro Biosystems, Inc. is a life sciences technology company that develops and manufactures automated microbial quality control solutions for the pharmaceutical, biotechnology, and personal care industries. The company operates primarily within the pharmaceutical quality assurance and manufacturing testing markets, with a focus on replacing traditional manual microbial testing methods with automated, data-driven systems. Its core offerings are designed to support regulatory compliance, improve operational efficiency, and accelerate product release timelines in highly regulated manufacturing environments.

The company’s primary commercial platform is the Growth Direct® System, an automated microbial detection and enumeration platform used for environmental monitoring, sterility testing, and bioburden testing in pharmaceutical manufacturing. Revenue is generated through system sales, recurring consumable products, software, validation services, and ongoing customer support contracts. Rapid Micro Biosystems serves global pharmaceutical manufacturers, including large biopharmaceutical companies and contract development and manufacturing organizations (CDMOs). Founded in 2006 and headquartered in Lexington, Massachusetts, the company evolved from a microbial automation startup into a publicly traded life sciences instrumentation company following its 2021 initial public offering on Nasdaq under the ticker RPID.